Findings

What do systematic reviews say?

1 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 0 · 0%Moderate 1 · 50%High 0 · 0%

Fingolimod (Direct evidence; 2 RCTs; 2355 participants) · relapsing multiple sclerosis

Rituximab as 'switching' probably leads to lower fingolimod compared with other disease‐modifying treatments (moderate certainty).

2 findings from 1 review

Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
HR 0.08 [0.02, 0.32]
256 participants
Moderate
Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
HR 0.26 [0.04, 1.69]
137 participants
Very low